← Back to Search

Monoclonal Antibodies

Transcriptomic Skin Analysis for Atopic Dermatitis (LEADS Trial)

Phase 4
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant and/or parent guardian must be able to understand and provide informed consent and assent (if applicable)
Participants must agree to apply a stable dose of a study provided topical moisturizer (Vanicream (TM)) at least twice daily between the Baseline Assessment and Day 7 Visits to a specified skin target area
Screening 1 day
Treatment 6 months
Follow Up at day 7 and days 168-224
Awards & highlights

LEADS Trial Summary

This trial will help researchers understand the different ways atopic dermatitis manifests, in order to better tailor treatments.

Who is the study for?
This trial is for individuals with mild to moderate-severe Atopic Dermatitis (AD). Eligible participants must understand and consent to the study, use FDA-approved birth control if applicable, apply Vanicream moisturizer twice daily, and adhere to asthma medications if they have asthma. Participants should not be pregnant or breastfeeding, have a history of certain cancers or keloids (adults), require systemic immunosuppressants recently, or have used other biologics or phototherapy close to the baseline visit.Check my eligibility
What is being tested?
The study aims to analyze gene expression in skin samples from AD patients responding to standard treatments like topical steroids and Dupilumab. It will compare these profiles between mild and severe cases over ten visits. Non-AD participants are controls. The primary goal is seeing if a specific skin endotype correlates with AD severity.See study design
What are the potential side effects?
Potential side effects may include irritation at the cream application site for Vanicream users; Triamcinolone could cause skin thinning or hormonal changes; Dupilumab might lead to injection site reactions, eye issues, or cold sores.

LEADS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I agree to regularly apply a specific moisturizer provided by the study.
I will continue my asthma medication throughout the study.
I am not pregnant, as confirmed by tests at my first and second visits.
I agree to use approved birth control methods during the study.

LEADS Trial Timeline

Screening ~ 1 day
Treatment ~ 6 months
Follow Up ~at day 7 and days 168-224
This trial's timeline: 1 day for screening, 6 months for treatment, and at day 7 and days 168-224 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Non-lesional skin tape transcriptome at Day 7
Secondary outcome measures
Non-lesional and lesional skin tape transcriptome at Day 7 and Days 168-224

Side effects data

From 2021 Phase 4 trial • 188 Patients • NCT04033367
Dermatitis Atopic
Accidental Overdose
Drug Hypersensitivity
Study treatment Arm
OLE Period: Placebo/Dupilumab
DB Period: Placebo
DB Period: Dupilumab
OLE Period: Dupilumab/Dupilumab

LEADS Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Experienced Dupilumab atopic dermatitis participantsExperimental Treatment1 Intervention
AD participants already on dupilumab (for >= 4 months prior to study entry (20 children, 40 adults)) at the start of the study will continue dupilumab treatment as prescribed by their physician outside of the study. After Day 7, long-term dupilumab participants may continue to apply topical steroids/moisturizer body-wide as needed per their physician's orders and will return for assessments and sampling at Days 63 and 140. At Day 140, participants will discontinue applying topical steroids to the specified target area and begin to apply Vanicream™ at least twice daily on the target skin area until their End of Study Assessment visit (Day 168)
Group II: Dupilumab-naïve atopic dermatitis participantsExperimental Treatment2 Interventions
On Day 7, dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment (non-sensitive regions)/ hydrocortisone 2.5% ointment (sensitive regions) twice daily to active lesions on non-target skin. Dupilumab-naïve AD participants will return for a Steroid Assessment Visit at Day 35, when response to triamcinolone will be evaluated at the target site by TAA and targeted EASI scoring, and overall management of AD body-wide by topical steroid/moisturizer treatment will be evaluated by EASI score.
Group III: Non-atopic dermatitis participantsActive Control1 Intervention
Approximately 150 will be non-AD controls (including approximately 50 children, 6-17 years of age, and 100 adults, = 18 years of age) Non-AD control participants will return for assessment visits at Days 0, 7, 35, 91, 140, and 168. Non-AD participants will apply Vanicream (TM) at least twice daily to the specified target skin area starting at Day 140 through the End of Study Assessment Visit (Day 168)
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,269 Previous Clinical Trials
5,480,869 Total Patients Enrolled
Donald Leung, M.D., Ph.D.Study ChairNational Jewish Health: Division of Pediatric Allergy and Clinical Immunology
2 Previous Clinical Trials
131 Total Patients Enrolled
Max A. Seibold, Ph.D.Study ChairNational Jewish Health: Division of Pediatric Allergy and Clinical Immunology

Media Library

Dupilumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05436535 — Phase 4
Atopic Dermatitis Research Study Groups: Dupilumab-naïve atopic dermatitis participants, Experienced Dupilumab atopic dermatitis participants, Non-atopic dermatitis participants
Atopic Dermatitis Clinical Trial 2023: Dupilumab Highlights & Side Effects. Trial Name: NCT05436535 — Phase 4
Dupilumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05436535 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have signed up for the experiment thus far?

"Affirmative. Data hosted on clinicaltrials.gov reveals that this experiment is actively seeking out patients, which commenced its recruitment process on November 21st 2022 and was recently revised on the 30th of the same month. Approximately 600 participants are needed from 10 distinct healthcare facilities."

Answered by AI

Are any additional participants being admitted to this clinical experiment?

"As indicated on clinicaltrials.gov, this medical trial is open for participant recruitment since November 21st 2022 and was most recently revised on the 30th of that same month."

Answered by AI

In what locales is this research endeavor being conducted?

"This clinical trial is available at Cincinnati Children's Hospital Medical Center: Asthma Center in Ohio, University of California, San Diego: Dermatology Clinical Trials Unit in La Jolla and National Jewish Health: Division of Pediatric Allergy and Clinical Immunology in Denver as well as 10 additional medical establishments."

Answered by AI

Has the Dupilumab drug been ratified by the FDA?

"There is ample evidence supporting the safety of dupilumab, so it achieved a rating of 3 on our team's scale. This medication has already been approved for clinical use."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
New York
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
What site did they apply to?
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology
University of Rochester Medical Center: Department of Dermatology
Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
How many prior treatments have patients received?

Why did patients apply to this trial?

tired of not being comfortable in my own skin. i dream of clear skin.
PatientReceived 1 prior treatment

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call
Most responsive sites:
  1. North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology: < 48 hours
~192 spots leftby Dec 2024